BridgeBio Pharma, Inc. (BBIO) vs Bio-Techne Corp (TECH)
- BridgeBio Pharma, Inc. BBIO 74.11 −0.22%
- Bio-Techne Corp TECH 72.79 +0.18%
BridgeBio Pharma, Inc. and Bio-Techne Corp are both Biotechnology companies. BridgeBio Pharma, Inc. is the larger, with a market value of $14.5B against $11.4B — 1.3× the size. BridgeBio Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Bio-Techne Corp trades at 62.2×. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 167.3% against −0.38%. Bio-Techne Corp has the higher net margin (15.0% vs −62.6%) and the higher return on invested capital (7.70% vs 0.00%). Across the 18 metrics below, Bio-Techne Corp leads on 12 and BridgeBio Pharma, Inc. on 6.
Valuation
Profitability
| Metric | BBIO | TECH | Biotechnology median |
|---|---|---|---|
| Gross margin | 94.34% | 65.77% | 65.16% |
| Operating margin | (38.52%) | 20.73% | 0.00% |
| Net margin | (62.62%) | 14.97% | 0.00% |
| Free cash flow margin | (39.11%) | 21.66% | 0.00% |
| Return on equity | 26.22% | 9.03% | (50.12%) |
| Return on assets | (37.48%) | 7.07% | (45.60%) |
| Return on invested capital | 0.00% | 7.70% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack